The SARM1 TIR domain produces glycocyclic ADPR molecules as minor products

PLoS One. 2024 Apr 18;19(4):e0302251. doi: 10.1371/journal.pone.0302251. eCollection 2024.

Abstract

Sterile alpha and TIR motif-containing 1 (SARM1) is a protein involved in programmed death of injured axons. Following axon injury or a drug-induced insult, the TIR domain of SARM1 degrades the essential molecule nicotinamide adenine dinucleotide (NAD+), leading to a form of axonal death called Wallerian degeneration. Degradation of NAD+ by SARM1 is essential for the Wallerian degeneration process, but accumulating evidence suggest that other activities of SARM1, beyond the mere degradation of NAD+, may be necessary for programmed axonal death. In this study we show that the TIR domains of both human and fruit fly SARM1 produce 1''-2' and 1''-3' glycocyclic ADP-ribose (gcADPR) molecules as minor products. As previously reported, we observed that SARM1 TIR domains mostly convert NAD+ to ADPR (for human SARM1) or cADPR (in the case of SARM1 from Drosophila melanogaster). However, we now show that human and Drosophila SARM1 additionally convert ~0.1-0.5% of NAD+ into gcADPR molecules. We find that SARM1 TIR domains produce gcADPR molecules both when purified in vitro and when expressed in bacterial cells. Given that gcADPR is a second messenger involved in programmed cell death in bacteria and likely in plants, we propose that gcADPR may play a role in SARM1-induced programmed axonal death in animals.

MeSH terms

  • Adenosine Diphosphate Ribose / metabolism
  • Animals
  • Armadillo Domain Proteins / genetics
  • Armadillo Domain Proteins / metabolism
  • Axons / metabolism
  • Bacteria / metabolism
  • Cytoskeletal Proteins / genetics
  • Cytoskeletal Proteins / metabolism
  • Drosophila melanogaster / metabolism
  • Humans
  • NAD* / metabolism
  • Wallerian Degeneration* / metabolism
  • Wallerian Degeneration* / pathology

Substances

  • NAD
  • Adenosine Diphosphate Ribose
  • Armadillo Domain Proteins
  • SARM1 protein, human
  • Cytoskeletal Proteins

Grants and funding

We thank A. Yaron, O. Abraham, N. Pursotham, and S. Hobbs for fruitful discussions on SARM1 activity and biochemical analysis of gcADPR signaling, as well as the Sorek and Kranzusch lab members for comments on the manuscript. R.S. was supported, in part, by the European Research Council (grant no. ERC-AdG GA 101018520), Israel Science Foundation (MAPATS Grant 2720/22), the Deutsche Forschungsgemeinschaft (SPP 2330, Grant 464312965), the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine, Dr. Barry Sherman Institute for Medicinal Chemistry, Miel de Botton, the Andre Deloro Prize, and the Knell Family Center for Microbiology. P.J.K. was supported, in part, by the Pew Biomedical Scholars program and The Mathers Foundation. G.O. was supported by the SAERI doctoral fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.